GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Virax Biolabs Group Ltd (NAS:VRAX) » Definitions » Earnings Yield (Joel Greenblatt) %

Virax Biolabs Group (Virax Biolabs Group) Earnings Yield (Joel Greenblatt) % : 0.00% (As of Sep. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Virax Biolabs Group Earnings Yield (Joel Greenblatt) %?

Virax Biolabs Group's Enterprise Value for the quarter that ended in Sep. 2023 was $0.73 Mil. Virax Biolabs Group's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 was $-6.90 Mil. Virax Biolabs Group's Earnings Yield (Joel Greenblatt) for the quarter that ended in Sep. 2023 was 0.00%.

The historical rank and industry rank for Virax Biolabs Group's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:

VRAX' s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -699.55   Med: 70.81   Max: 1788.91
Current: 204.08

During the past 4 years, the highest Earnings Yield (Joel Greenblatt) of Virax Biolabs Group was 1788.91%. The lowest was -699.55%. And the median was 70.81%.

VRAX's Earnings Yield (Joel Greenblatt) % is not ranked
in the Biotechnology industry.
Industry Median: -15.455 vs VRAX: 204.08

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Virax Biolabs Group's Forward Rate of Return (Yacktman) % for the quarter that ended in Sep. 2023 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.


Virax Biolabs Group Earnings Yield (Joel Greenblatt) % Historical Data

The historical data trend for Virax Biolabs Group's Earnings Yield (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Virax Biolabs Group Earnings Yield (Joel Greenblatt) % Chart

Virax Biolabs Group Annual Data
Trend Mar20 Mar21 Mar22 Mar23
Earnings Yield (Joel Greenblatt) %
- - - -400.00

Virax Biolabs Group Semi-Annual Data
Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
Earnings Yield (Joel Greenblatt) % Get a 7-Day Free Trial - - - -400.00 -

Competitive Comparison of Virax Biolabs Group's Earnings Yield (Joel Greenblatt) %

For the Biotechnology subindustry, Virax Biolabs Group's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Virax Biolabs Group's Earnings Yield (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Virax Biolabs Group's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Virax Biolabs Group's Earnings Yield (Joel Greenblatt) % falls into.



Virax Biolabs Group Earnings Yield (Joel Greenblatt) % Calculation

In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.

Virax Biolabs Groups Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Mar. 2023 is calculated as

Earnings Yield (Joel Greenblatt)=EBIT/Enterprise Value
=-5.442/1.38245334
=-393.65 %

For company reported semi-annually or annually, GuruFocus only calculate annual data for Earnings Yield (Joel Greenblatt) and apply the annual figure to corresponding quarter.



Virax Biolabs Group  (NAS:VRAX) Earnings Yield (Joel Greenblatt) % Explanation

Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.

Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.


Be Aware

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

Forward Rate of Return (Yacktman) % based on Don Yacktman's definition is a better measure of the expected rate of return for a stock.


Virax Biolabs Group Earnings Yield (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Virax Biolabs Group's Earnings Yield (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Virax Biolabs Group (Virax Biolabs Group) Business Description

Industry
Traded in Other Exchanges
N/A
Address
20 North Audley Street, London, GBR, W1K 6LX
Virax Biolabs Group Ltd is a innovative biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against major global viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.